Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Libman-Sacks Endocarditis

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Libman-Sacks Endocarditis

Abdisamad M. Ibrahim et al.
Free Books & Documents

Excerpt

Libman-Sacks endocarditis (LSE) was first described in four patients in 1924 by Emanuel Libman and Benjamin Sacks in New york. Libman-Sacks endocarditis, also named as nonbacterial thrombotic endocarditis (NBTE) or marantic endocarditis, describes a broad spectrum of pathologies ranging from very small particles seen only with a microscope to large vegetations on previously normal heart valves (most often aortic and mitral). This term describes vegetations on the cardiac valves that are sterile and doesn't show any signs of infection. The initial development of Libman-Sacks endocarditis appears to be an endothelial injury in the setting of a hypercoagulable state. So they are mainly observed in patients with malignancies (mainly solid tumor: adenocarcinoma), systemic lupus erythematosus (SLE), which was first described in women in 1985, and antiphospholipid antibody syndrome (APS). Other terms used to describe these vegetations include verrucous endocarditis. Libman-Sacks endocarditis most commonly affects the mitral followed by aortic valves, but other valves may also be involved.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Abdisamad Ibrahim declares no relevant financial relationships with ineligible companies.

Disclosure: Momin Siddique declares no relevant financial relationships with ineligible companies.

References

    1. Yoo BW, Lee SW, Song JJ, Park YB, Jung SM. Clinical characteristics and long-term outcomes of Libman-Sacks endocarditis in patients with systemic lupus erythematosus. Lupus. 2020 Aug;29(9):1115-1120. - PubMed
    1. Zuily S, Huttin O, Mohamed S, Marie PY, Selton-Suty C, Wahl D. Valvular heart disease in antiphospholipid syndrome. Curr Rheumatol Rep. 2013 Apr;15(4):320. - PubMed
    1. Lenz CJ, Mankad R, Klarich K, Kurmann R, McBane RD. Antiphospholipid syndrome and the relationship between laboratory assay positivity and prevalence of non-bacterial thrombotic endocarditis: A retrospective cohort study. J Thromb Haemost. 2020 Jun;18(6):1408-1414. - PubMed
    1. Riancho-Zarrabeitia L, Martínez-Taboada VM, Rúa-Figueroa I, Alonso F, Galindo-Izquierdo M, Ovalles J, Olivé-Marqués A, Mena Vázquez N, Calvo-Alén J, Menor Almagro R, Tomero Muriel E, Uriarte Isacelaya E, Boteanu A, Andres M, Freire González M, Santos Soler G, Ruiz-Lucea ME, Ibáñez-Barceló M, Castellví I, Galisteo C, Quevedo Vila V, Raya E, Narváez J, Expósito L, Hernández Beriaín JA, Horcada L, Aurrecoechea E, Pego Reigosa JM. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients? Clin Exp Rheumatol. 2021 May-Jun;39(3):555-563. - PubMed
    1. Roldan CA, Sibbitt WL, Qualls CR, Jung RE, Greene ER, Gasparovic CM, Hayek RA, Charlton GA, Crookston K. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging. 2013 Sep;6(9):973-83. - PMC - PubMed

Publication types

LinkOut - more resources